NCT01926197View on ClinicalTrials.gov

Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

August 14, 2013

Primary Completion Date

September 30, 2021

Study Completion Date

September 30, 2022

Conditions
Pancreatic Cancer
Interventions
DRUG

Oxaliplatin

Oxaliplatin 85 mg/m² IV over 2 hours on Day 1 of a 14-day cycle.

DRUG

Irinotecan

Irinotecan 180 mg/m² IV over 90 minutes on Day 1 of a 14-day cycle.

DRUG

Leucovorin

Leucovorin 400 mg/m² IV over 2 hours on Day 1 of a 14-day cycle.

DRUG

5FU

5FU 2,400 mg/m² IV over 46 to 48 hours starting on Day 1 of a 14-day cycle.

RADIATION

Stereotactic Body Radiotherapy (SBRT)

Radiotherapy treatment starting about 8 weeks after modified FOLFIRINOX induction chemotherapy, administered as 5 fractions of 8 Grey (Gy) each, on 5 separate days.

Trial Locations (9)

29425

Medical University of South Carolina, Charleston

60153

UCLA, Los Angeles

Loyola University, Maywood

75390

University of Texas Southwestern Medical Center, Dallas

94143

UCSF, San Francisco

94305

Stanford University, School of Medicine, Stanford

98107

Swedish Cancer Institute, Seattle

V5Z 4E6

BC Cancer Agency, Vancouver

Unknown

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors
lead

Stanford University

OTHER

NCT01926197 - Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer | Biotech Hunter | Biotech Hunter